Back to top
more

Tandem Diabetes Care (TNDM)

(Real Time Quote from BATS)

$44.33 USD

44.33
115,107

+0.03 (0.07%)

Updated Aug 27, 2024 11:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

What's in the Offing for LabCorp's (LH) Earnings in Q4?

With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.

What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?

Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.

Is a Beat in the Cards for Humana's (HUM) Earnings in Q4?

Humana's (HUM) fourth-quarter results are likely to reflect lower membership, partly offset by higher revenues.

The Zacks Analyst Blog Highlights: Agilysys, Tandem Diabetes Care, Enphase Energy, Forterra and MagnaChip Semiconductor

The Zacks Analyst Blog Highlights: Agilysys, Tandem Diabetes Care, Enphase Energy, Forterra and MagnaChip Semiconductor

Nalak Das headshot

5 Top-Ranked Growth Stocks for February That Have Jumped YTD

Several positive factors have strengthened investors' confidence in risky assets like equities. A few top-ranked growth stocks surged in January and still have strong upside left.

Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?

Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.

What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?

Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.

Zacks.com featured highlights include: Synaptics, MagnaChip Semiconductor, Tandem Diabetes Care and International Money Express

Zacks.com featured highlights include: Synaptics, MagnaChip Semiconductor, Tandem Diabetes Care and International Money Express

Moving Average Crossover Alert: Tandem Diabetes Care

Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Check 4 Best Liquid Bets to Power Your Portfolio

Four top-ranked liquid stocks that investors can bank on for fat returns.

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.

Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?

Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.

Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?

Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.

Moving Average Crossover Alert: Tandem Diabetes Care

Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.

Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?

Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.

Sriparna Ghosal headshot

Diabetes Management Gains FDA Attention: 3 Stocks in Focus

The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.

Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry

Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.

Trina Mukherjee headshot

6 MedTech Stocks That are Set to Beat the Market in 2020

Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.

Tandem Diabetes Sees Hammer Chart Pattern: Time to Buy?

Tandem Diabetes Care has been struggling lately, but the selling pressure may be coming to an end soon.

Tandem Diabetes Gets FDA Nod for t:slim X2 Insulin Pump

The FDA nod for Tandem Diabetes' (TNDM) t:slim X2 insulin pump with Control-IQ will speed up its pump shipments within the United States and grow its clientele.

Trina Mukherjee headshot

Digital Diabetes Management Gains Momentum: 3 Stocks in Focus

With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.

Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

Investor confidence in Tandem Diabetes (TNDM) stock is at a high, thanks to solid prospects.

Will Tandem Diabetes Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Tandem Diabetes Care.